TheranosticTrials.org

Clinical Trial · NCT05161728

PSMA Response in Metastasized Hormone Sensitive Prostate Cancer

Overview

PSMA-PET/CT response measurements after LHRH agonist and upfront therapy in men diagnosed with de novo metastasized hormonal sensitive prostate cancer.

Sponsor

UMC Utrecht

Phase

N/A

Contacts

Roderick van den Bergh, MD PhD (CONTACT)

roodvdb@hotmail.com

+31623456800

Marnix Lam, MD PhD (STUDY_CHAIR)

ClinicalTrials.gov

NCT05161728

Drug / Compound

PSMA-11

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules
Chelator: HBED-CC

Eligibility

Inclusion

  • Indicated to start on hormonal therapy (any LHRH agonist or antagonist).
  • * Men \>18 years of age.
  • Written and signed informed consent.
  • Histological confirmed diagnosis of adenocarcinoma of the prostate.
  • Mentally competent and understanding of benefits and potential burden of the study.

Exclusion

  • Any unrelated illness (e.g. active infection, inflammation or laboratory abnormalities) that in the judgment of the investigator will significantly affect patient's clinical status and/or outcome of the study.
  • Any known allergy for the upfront therapy.
  • * Concomitant malignancy (except from BCC of the skin).
  • History of prior diagnosed or treated PCa.
  • Any known allergy for LHRH agonist or antagonist.